Beximco Pharmaceuticals Limited Stock London S.E.

Equities

BXP

US0885792061

Pharmaceuticals

Market Closed - London S.E. 11:35:12 2024-04-26 am EDT 5-day change 1st Jan Change
36.5 GBX 0.00% Intraday chart for Beximco Pharmaceuticals Limited -1.35% -12.05%
Sales 2024 * 44.55B 405M Sales 2025 * 50.49B 459M Capitalization 51.79B 471M
Net income 2024 * 5.13B 46.67M Net income 2025 * 6B 54.56M EV / Sales 2024 * 1.3 x
Net Debt 2024 * 5.99B 54.5M Net Debt 2025 * 884M 8.04M EV / Sales 2025 * 1.04 x
P/E ratio 2024 *
9.44 x
P/E ratio 2025 *
7.69 x
Employees 5,700
Yield 2024 *
3.45%
Yield 2025 *
4.31%
Free-Float 76.68%
More Fundamentals * Assessed data
Dynamic Chart
1 week-1.35%
Current month-6.41%
1 month-6.41%
3 months+4.29%
6 months-5.19%
Current year-12.05%
More quotes
1 week
36.00
Extreme 36
38.00
1 month
35.00
Extreme 35
40.00
Current year
33.56
Extreme 33.555
42.00
1 year
33.30
Extreme 33.3
45.00
3 years
33.30
Extreme 33.3
131.00
5 years
28.07
Extreme 28.0695
131.00
10 years
10.10
Extreme 10.1009
131.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 61 89-12-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Founder - 75-12-31
Founder - 75-12-31
Chief Executive Officer - 84-12-31
More insiders
Date Price Change Volume
24-04-26 36.5 0.00% 105,000
24-04-25 36.5 0.00% 5,473
24-04-24 36.5 -1.35% 10,477
24-04-23 37 0.00% 23,201
24-04-22 37 0.00% 0

Delayed Quote London S.E., April 26, 2024 at 11:35 am EDT

More quotes
Beximco Pharmaceuticals Ltd. is a manufacturer and exporter of medicines in Bangladesh. The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a range of therapeutic categories. It offers products in different dosage forms including solid, liquid, cream and ointment, suppositories, metered dose inhaler, dry powder inhaler, nasal spray, sterile, lyophilized injectable and large volume intravenous fluids. It also manufactures active pharmaceutical ingredients (APIs) and renders contract manufacturing services to other companies. It produces different presentations, and the portfolio encompasses all key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal and others. The Company's products include Atrizin, Nomos, Azithrocin, Ceftoril, Bemsivir, Viraflu, Viracin, Rilovir, Flurium, Nervalin, Seropam, Nightus, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
116.1 BDT
Average target price
153.5 BDT
Spread / Average Target
+32.21%
Consensus

Annual profits - Rate of surprise